Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 175

GlobalBees buzzes in $150m

FirstCry has led a series A equity and debt round for GlobalBees, an e-commerce aggregator co-founded by FirstCry's CEO.

Jul 20, 2021

Ribon Therapeutics cribs $65m

Osage University Partners has returned to back the cancer and inflammatory drug developer based on research from multiple universities.

Jul 19, 2021

Daily Deal Round Up: July 19, 2021

Debt repayment platform developer InDebted received $18.4m from investors including MassMutual, while corporate-backed AdaptiveMobile, Immersal and Pocket Casts are all being acquired.

Jul 19, 2021

Lenskart to leverage $220m in funding

Temasek and Falcon Edge Capital co-led a late-stage round for the SoftBank-backed eyewear retailer valuing it at $2.5bn.

Jul 19, 2021

Mei Wei makes off with over $155m

New Hope Group was among the participants in the dental clinic franchise owner's series B round, which lifted its overall funding past $200m.

Jul 19, 2021

Genvid generates $113m series C round

Samsung, NTT Docomo and Huya helped the livestreaming technology provider close a round that took its overall funding to $166m.

Jul 19, 2021

OM1 turns to Kaiser Permanente in $85m round

Kaiser Permanente co-led the medical data software provider's latest round, pushing its total funding past the $170m mark.

Jul 19, 2021

Wugen wraps up $172m series B

WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

Jul 19, 2021

Ribon Therapeutics cribs $65m

Johnson & Johnson, Novartis and Takeda returned to back the cancer and inflammatory drug developer and were joined by investors including AbbVie, Alphabet and Bristol Myers Squibb.

Jul 19, 2021

YuLife livens up with $70m

Target Global led the RGA-backed gamified life insurance platform’s series B round, which valued it at almost $350m.

Jul 19, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here